1. Home
  2. IKNA vs SRFM Comparison

IKNA vs SRFM Comparison

Compare IKNA & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • SRFM
  • Stock Information
  • Founded
  • IKNA 2016
  • SRFM 2011
  • Country
  • IKNA United States
  • SRFM United States
  • Employees
  • IKNA N/A
  • SRFM N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • SRFM Transportation Services
  • Sector
  • IKNA Health Care
  • SRFM Consumer Discretionary
  • Exchange
  • IKNA Nasdaq
  • SRFM Nasdaq
  • Market Cap
  • IKNA 61.8M
  • SRFM 58.2M
  • IPO Year
  • IKNA 2021
  • SRFM 2023
  • Fundamental
  • Price
  • IKNA $1.08
  • SRFM $2.50
  • Analyst Decision
  • IKNA Buy
  • SRFM Strong Buy
  • Analyst Count
  • IKNA 2
  • SRFM 3
  • Target Price
  • IKNA $3.00
  • SRFM $6.02
  • AVG Volume (30 Days)
  • IKNA 95.3K
  • SRFM 87.3K
  • Earning Date
  • IKNA 05-20-2025
  • SRFM 05-13-2025
  • Dividend Yield
  • IKNA N/A
  • SRFM N/A
  • EPS Growth
  • IKNA N/A
  • SRFM N/A
  • EPS
  • IKNA N/A
  • SRFM N/A
  • Revenue
  • IKNA N/A
  • SRFM $119,425,000.00
  • Revenue This Year
  • IKNA N/A
  • SRFM N/A
  • Revenue Next Year
  • IKNA N/A
  • SRFM $45.73
  • P/E Ratio
  • IKNA N/A
  • SRFM N/A
  • Revenue Growth
  • IKNA N/A
  • SRFM 97.38
  • 52 Week Low
  • IKNA $0.97
  • SRFM $0.90
  • 52 Week High
  • IKNA $1.94
  • SRFM $6.72
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 37.62
  • SRFM 44.85
  • Support Level
  • IKNA $1.22
  • SRFM $2.34
  • Resistance Level
  • IKNA $1.29
  • SRFM $2.55
  • Average True Range (ATR)
  • IKNA 0.09
  • SRFM 0.15
  • MACD
  • IKNA -0.01
  • SRFM 0.05
  • Stochastic Oscillator
  • IKNA 1.75
  • SRFM 61.90

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About SRFM Surf Air Mobility Inc.

Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.

Share on Social Networks: